Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $3.50 from $6 and keeps a Buy rating on the shares post the Q3 report. Although the company lowered its annual revenue guidance for the third consecutive quarter, Canaccord remains constructive, saying Akoya appears capable of returning to growth in the near term. The primary causes of the Q3 shortfall were extended sales cycles and limited capital equipment funding, adn the company’s recent sales force restructure and related transition led to some disruption, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences Reports Q3 2024 Financial Results
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Akoya Biosciences reports Q3 EPS (21c), consensus (20c)
- Akoya Biosciences lowers FY24 revenue view to $80M-$85M, consensus $98.19M
- AKYA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
